Travere pays Everest $112M upfront to grow rare kidney disease pipeline

FierceBiotechASCO: Roche, head held high, details oral SERD's first-line flop in breast cancer

BioPharma DiveFulcrum exploring a potential sale after FDA sidelined its sickle cell drug

Endpoints NewsWhat’s next for VEGF? #ASCO26 offered clues, but answers will have to wait

FierceBiotechTravere scales Everest with $1.1B deal for BTK inhibitor aimed at rare kidney diseases

Endpoints NewsMale contraception startup closes $92.5M Series B; Novartis bets on actinium

Endpoints NewsTravere pays Everest $112M upfront to grow rare kidney disease pipeline

Endpoints NewsLegend Biotech shares first in vivo CAR-T data, its next act after Carvykti

FierceBiotechFulcrum scraps SCD program, considers options after FDA takes hard line on safety risks

FierceBiotechASCO: Cardiff posts updated colorectal cancer data ahead of pivotal push

PharmaVoiceAs amyloid falls out of favor, here’s where Alzheimer’s R&D is headed next

BioWorldJanssen Pharmaceutica reports new TMEM175 activators

BioWorldBlossomhill Therapeutics discovers new EGFR mutant inhibitors